714230-90-7

Basic information

• Product Name: 4-[2-(1-PYRROLIDINYL)ETHOXY]-BENZENEACETIC ACID
• Synonyms: 4-[2-(1-PYRROLIDINYL)ETHOXY]-BENZENEACETIC ACID
• CAS NO: 714230-90-7
• Molecular Formula: C₁₄H₁₉NO₃
• Molecular Weight: 249.31
• Mol File: 714230-90-7.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 422.4 °C at 760 mmHg
• Flash Point: 209.2 °C
• Appearance: /
• Density: 1.169 g/cm³
• Vapor Pressure: 6.9E-08mmHg at 25°C
• Refractive Index: 1.557
• CAS DataBase Reference: 4-[2-(1-PYRROLIDINYL)ETHOXY]-BENZENEACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[2-(1-PYRROLIDINYL)ETHOXY]-BENZENEACETIC ACID(714230-90-7)
• EPA Substance Registry System: 4-[2-(1-PYRROLIDINYL)ETHOXY]-BENZENEACETIC ACID(714230-90-7)

Safety Data

• Hazardous Substances Data: 714230-90-7(Hazardous Substances Data)

Usage

General Description

4-[2-(1-Pyrrolidinyl)ethoxy]-benzeneacetic acid is a chemical compound with the molecular formula C16H21NO3. It is commonly known as ximoprofen and belongs to the class of nonsteroidal anti-inflammatory drugs (NSAIDs). Ximoprofen is used for its analgesic and anti-inflammatory properties and is commonly prescribed for the treatment of arthritis and other inflammatory conditions. The compound works by inhibiting the production of prostaglandins, which are responsible for pain and inflammation in the body. Ximoprofen is available in oral dosage forms such as tablets and capsules and is typically used for short-term relief of pain and inflammation.

InChI:InChI=1/C14H19NO3/c16-14(17)11-12-3-5-13(6-4-12)18-10-9-15-7-1-2-8-15/h3-6H,1-2,7-11H2,(H,16,17)

Upstream product

• 42058-70-8 methyl [4-(2-chloroethoxy)phenyl]acetate 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 
• 714230-89-4 methyl [4-(2-pyrrolidin-1-ylethoxy)phenyl]acetate 

Relevant articles and documents

3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding

Abnormal proliferation mediated by disruption of the normal cell cycle mechanisms is a hallmark of virtually all cancer cells. Compounds targeting complexes between cyclin-dependent kinases (CDK) and cyclins, such as CDK2/cyclin A and CDK2/cyclin E, and inhibiting their kinase activity are regarded as promising antitumor agents to complement the existing therapies. From a high-throughput screening effort, we identified a new class of CDK2/cyclin A/E inhibitors. The hit-to-lead expansion of this class is described. X-ray crystallographic data of early compounds in this series, as well as in vitro testing funneled for rapidly achieving in vivo efficacy, led to a nanomolar inhibitor of CDK2/cyclin A (N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2-naphthyl)acetamide (41), PNU-292137, IC50 = 37 nM) with in vivo antitumor activity (TGI > 50%) in a mouse xenograft model at a dose devoid of toxic effects.